|
|
11 Hurley Street
Cambridge, MA 02141 USA
phone:
(617) 234-6500
fax:
(617) 234-6505 |
| Symbol |
BPUR |
| Exchange |
NASDAQ |
| Founded |
0 |
| Employees |
164 |
|
|
www.biopure.com |
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Biopure Corporation is a developer of oxygen therapeutics. |
 |
| Management |
| Zafiris G. Zafirelis, Chairman, President and Chief Executive Officer; Francis H. Murphy, Chief Financial Officer; Jane Kober
Senior Vice President, General Counsel and Secretary; Geoffrey J. Filbey, Vice President, Engineering; A. Gerson Greenburg, M.D., Ph.D., Vice President, Medical Affairs; W. Richard Light, Ph.D., Vice President, Technology Development; Virginia T. Rentko, V.M.D., Vice President, Preclinical Development; Barry L. Scott, Vice President, Business Development |
|
|
|
|
| Keywords |
| oxygen, blood substitutes, hemoglobin |
|
|
|
|
Description |
| Biopure Corporation is a developer, manufacturer and supplier of a new class of pharmaceuticals, called oxygen therapeutics, which are intravenously administered to deliver oxygen to the body's tissues. Using its proprietary technology, the Company has developed and manufactures two products: Hemopure (hemoglobin glutamer - 250 (bovine), or HBOC-201) for human use, and Oxyglobin (hemoglobin glutamer - 200 (bovine), or HBOC-301) for veterinary use. Biopure's products are made from hemoglobin that has been extracted from bovine red blood cells and then purified, chemically modified and cross-linked for stability. The resulting hemoglobin solutions do not contain red blood cells and, for the final product, are formulated in a balanced salt solution similar to Ringer's lactate. |
 |
 |
|
|
|
|